en-label, proof-of-concept study designed to evaluate the feasibility, safety, and acceptability of a prophylactic fish oil-enriched nutritional supplement (Fresubin Supportan) in patients with head and neck cancer (HNC) undergoing curative-intent chemoradiotherapy (CRT) at the University of Kansas Medical Center. The study involves daily supplementation starting two weeks prior to CRT and continuing throughout CRT, alongside weekly nutrition counseling.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Recruitment rate
Timeframe: Through study completion, approximately 18 months
Adherence Rate
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Retention Rate
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Adverse Events
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Supplement Acceptability
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Supplement Discontinuation due to AEs
Timeframe: From baseline (Week -2) through 3 months post-chemoradiotherapy